A glycolytic metabolite that drives BRCA2 haploinsufficiency.

Abstract excerpt

Many types of tumor cells alter metabolic pathways to meet their energy and biosynthetic demands for proliferation or stress adaptation. In this issue of Cell, Kong et al. find that the glycolytic metabolite methylglyoxal causes cancer-associated mutant single-base substitution features by inducing BRCA2 proteolysis, leading to functional haploinsufficiency of BRCA2.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to BRCA2 Protein
• Share to Glycolysis
• Share to Haploinsufficiency